CUSTOMER: Myogen Therapeautics, LLC
Myogen, Inc. was founded as a developer of small molecule therapeutics to treat cardiovascular diseases with two strong drug candidates to treat pulmonary hypertension and resistant hypertension. Myogen was eventaully sold to Gilead Sciences Inc. for $2.6 billion cash.
Myogen is focused on research around the genetic causes of cardiovascular disease. To combine the concept of heart and genetics, we took the calligraphic-looking strokes of the double-helix DNA and cloned, twisted and reformed them into a medically-accurate representation of a human heart to match each other stylistically. The important message of the tagline was added to bring clairty to what Myogen does, “Innovative therapies targeting heart muscle disease”.